Please enable JavaScript to continue using this application.

Compare $IKT vs $RCKT | Chartloom

Compare

$IKT vs $RCKT

Inhibikase Therapeutics Inc · Rocket Pharmaceuticals Inc

IKT

Inhibikase Therapeutics Inc

RCKT

Rocket Pharmaceuticals Inc

Compare $IKT vs $RCKT

Comparing Inhibikase Therapeutics Inc and Rocket Pharmaceuticals Inc

IKTInhibikase Therapeutics Inc

RCKTRocket Pharmaceuticals Inc

IKTInhibikase Therapeutics Inc

Market cap

$309M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

1.0%

52W performance

18.7%

FCF yield

-13.8%

RCKTRocket Pharmaceuticals Inc

Market cap

$280M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

34.18x

Rev growth (TTM)

—

YTD performance

-26.0%

52W performance

-24.5%

FCF yield

-61.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IKT

RCKT

Detailed metrics comparison

IKT

Inhibikase Therapeutics Inc

RCKT

Rocket Pharmaceuticals Inc

Market Cap

IKT$309M

RCKT$280M

Enterprise Value

IKT$278M

RCKT$76M

Price

IKT$1.97

RCKT$2.56

P/E Ratio

IKTN/A

RCKTN/A

P/S Ratio

IKT872.10x

RCKT0.00x

EV/Sales

IKT774.58x

RCKT0.00x

EV/EBITDA

IKT0.00x

RCKT8.60x

P/B Ratio

IKT1.82x

RCKT0.76x

P/FCF Ratio

IKTN/A

RCKTN/A

EV/FCF

IKT-6.53x

RCKT-0.45x

PEG Ratio

IKTN/A

RCKTN/A

Forward P/E (NTM)

IKTN/A

RCKTN/A

Forward P/S (NTM)

IKTN/A

RCKT34.18x

Revenue (TTM)

IKT$0

RCKT$0

Revenue Growth (YoY)

IKTN/A

RCKTN/A

Forward Rev Growth

IKT0.0%

RCKT833.4%

Gross Margin (TTM)

IKT0.0%

RCKT0.0%

Operating Margin (TTM)

IKT0.0%

RCKT0.0%

EBITDA Margin (TTM)

IKT0.0%

RCKT0.0%

Net Margin (TTM)

IKT0.0%

RCKT0.0%

FCF Margin (TTM)

IKTN/A

RCKTN/A

Net Income (TTM)

IKT$-44M

RCKT$-17M

FCF (TTM)

IKT$-43M

RCKT$-171M

EPS (TTM)

IKT-$0.25

RCKT-$0.15

ROE (TTM)

IKT-4690.0%

RCKT-576.0%

ROA (TTM)

IKT-4348.0%

RCKT-490.0%

ROIC (TTM)

IKT-4690.0%

RCKT-538.0%

Cash

IKT$31M

RCKT$225M

Debt

IKT$0

RCKT$21M

Net Cash/Debt

IKT$31M

RCKT$203M

Current Ratio (TTM)

IKT15.82x

RCKT9.24x

Quick Ratio (TTM)

IKT15.50x

RCKT9.06x

Debt/Equity (TTM)

IKT0.00x

RCKT0.06x

Debt/Assets (TTM)

IKT0.0%

RCKT0.0%

Interest Coverage (TTM)

IKTN/A

RCKTN/A

Net Debt/EBITDA (TTM)

IKT0.00x

RCKT0.00x

Beta

IKT0.92

RCKT0.48

52W Performance

IKT18.7%

RCKT-24.5%

YTD Performance

IKT1.0%

RCKT-26.0%

% from 52W High

IKT-24.5%

RCKT-53.0%

% from 52W Low

IKT48.1%

RCKT5.8%

Asset Turnover (TTM)

IKT0.01x

RCKT0.00x

FCF Yield (TTM)

IKT-13.8%

RCKT-61.0%

Earnings Yield (TTM)

IKT-14.3%

RCKT-6.2%

Dividend Yield (TTM)

IKTN/A

RCKTN/A

Rule of 40

IKT0.0

RCKT0.0

EV/GP/RG

IKTN/A

RCKTN/A

Ticker research

View IKT research View RCKT research

Metric	IKT Inhibikase Therapeutics Inc	RCKT Rocket Pharmaceuticals Inc
Market & Valuation
Market Cap	$309M	$280M
Enterprise Value	$278M	$76M
Price	$1.97	$2.56
P/E Ratio	N/A	N/A
P/S Ratio	872.10x	0.00x
EV/Sales	774.58x	0.00x
EV/EBITDA	0.00x	8.60x
P/B Ratio	1.82x	0.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.53x	-0.45x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	34.18x
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	833.4%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-44M	$-17M
FCF (TTM)	$-43M	$-171M
EPS (TTM)	-$0.25	-$0.15
ROE (TTM)	-4690.0%	-576.0%
ROA (TTM)	-4348.0%	-490.0%
ROIC (TTM)	-4690.0%	-538.0%
Financial Health
Cash	$31M	$225M
Debt	$0	$21M
Net Cash/Debt	$31M	$203M
Current Ratio (TTM)	15.82x	9.24x
Quick Ratio (TTM)	15.50x	9.06x
Debt/Equity (TTM)	0.00x	0.06x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.92	0.48
52W Performance	18.7%	-24.5%
YTD Performance	1.0%	-26.0%
% from 52W High	-24.5%	-53.0%
% from 52W Low	48.1%	5.8%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-13.8%	-61.0%
Earnings Yield (TTM)	-14.3%	-6.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View IKT research	View RCKT research

Valuation

P/S Ratio

RCKT

0.00x

IKT

872.10x

EV/FCF

IKT

-6.53x

RCKT

-0.45x

Growth & revenue

Forward Revenue Growth

RCKT

833.4%

IKT

0.0%

Profitability & performance

Gross Margin

IKT

0.0%

RCKT

0.0%

ROE

RCKT

-576.0%

IKT

-4690.0%

FCF Yield %

IKT

-13.8%

RCKT

-61.0%

52-Week Performance

IKT

18.7%

RCKT

-24.5%

Detailed metrics comparison

IKT

Inhibikase Therapeutics Inc

RCKT

Rocket Pharmaceuticals Inc

Market Cap

IKT$309M

RCKT$280M

Enterprise Value

IKT$278M

RCKT$76M

Price

IKT$1.97

RCKT$2.56

P/E Ratio

IKTN/A

RCKTN/A

P/S Ratio

IKT872.10x

RCKT0.00x

EV/Sales

IKT774.58x

RCKT0.00x

EV/EBITDA

IKT0.00x

RCKT8.60x

P/B Ratio

IKT1.82x

RCKT0.76x

P/FCF Ratio

IKTN/A

RCKTN/A

EV/FCF

IKT-6.53x

RCKT-0.45x

PEG Ratio

IKTN/A

RCKTN/A

Forward P/E (NTM)

IKTN/A

RCKTN/A

Forward P/S (NTM)

IKTN/A

RCKT34.18x

Revenue (TTM)

IKT$0

RCKT$0

Revenue Growth (YoY)

IKTN/A

RCKTN/A

Forward Rev Growth

IKT0.0%

RCKT833.4%

Gross Margin (TTM)

IKT0.0%

RCKT0.0%

Operating Margin (TTM)

IKT0.0%

RCKT0.0%

EBITDA Margin (TTM)

IKT0.0%

RCKT0.0%

Net Margin (TTM)

IKT0.0%

RCKT0.0%

FCF Margin (TTM)

IKTN/A

RCKTN/A

Net Income (TTM)

IKT$-44M

RCKT$-17M

FCF (TTM)

IKT$-43M

RCKT$-171M

EPS (TTM)

IKT-$0.25

RCKT-$0.15

ROE (TTM)

IKT-4690.0%

RCKT-576.0%

ROA (TTM)

IKT-4348.0%

RCKT-490.0%

ROIC (TTM)

IKT-4690.0%

RCKT-538.0%

Cash

IKT$31M

RCKT$225M

Debt

IKT$0

RCKT$21M

Net Cash/Debt

IKT$31M

RCKT$203M

Current Ratio (TTM)

IKT15.82x

RCKT9.24x

Quick Ratio (TTM)

IKT15.50x

RCKT9.06x

Debt/Equity (TTM)

IKT0.00x

RCKT0.06x

Debt/Assets (TTM)

IKT0.0%

RCKT0.0%

Interest Coverage (TTM)

IKTN/A

RCKTN/A

Net Debt/EBITDA (TTM)

IKT0.00x

RCKT0.00x

Beta

IKT0.92

RCKT0.48

52W Performance

IKT18.7%

RCKT-24.5%

YTD Performance

IKT1.0%

RCKT-26.0%

% from 52W High

IKT-24.5%

RCKT-53.0%

% from 52W Low

IKT48.1%

RCKT5.8%

Asset Turnover (TTM)

IKT0.01x

RCKT0.00x

FCF Yield (TTM)

IKT-13.8%

RCKT-61.0%

Earnings Yield (TTM)

IKT-14.3%

RCKT-6.2%

Dividend Yield (TTM)

IKTN/A

RCKTN/A

Rule of 40

IKT0.0

RCKT0.0

EV/GP/RG

IKTN/A

RCKTN/A

Ticker research

View IKT research View RCKT research

Metric	IKT Inhibikase Therapeutics Inc	RCKT Rocket Pharmaceuticals Inc
Market & Valuation
Market Cap	$309M	$280M
Enterprise Value	$278M	$76M
Price	$1.97	$2.56
P/E Ratio	N/A	N/A
P/S Ratio	872.10x	0.00x
EV/Sales	774.58x	0.00x
EV/EBITDA	0.00x	8.60x
P/B Ratio	1.82x	0.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.53x	-0.45x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	34.18x
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	833.4%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-44M	$-17M
FCF (TTM)	$-43M	$-171M
EPS (TTM)	-$0.25	-$0.15
ROE (TTM)	-4690.0%	-576.0%
ROA (TTM)	-4348.0%	-490.0%
ROIC (TTM)	-4690.0%	-538.0%
Financial Health
Cash	$31M	$225M
Debt	$0	$21M
Net Cash/Debt	$31M	$203M
Current Ratio (TTM)	15.82x	9.24x
Quick Ratio (TTM)	15.50x	9.06x
Debt/Equity (TTM)	0.00x	0.06x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.92	0.48
52W Performance	18.7%	-24.5%
YTD Performance	1.0%	-26.0%
% from 52W High	-24.5%	-53.0%
% from 52W Low	48.1%	5.8%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-13.8%	-61.0%
Earnings Yield (TTM)	-14.3%	-6.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View IKT research	View RCKT research